Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 3/20 | 0.52 |
| ▸ | SORD | Q00796 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649628 | 0.86 | DKK1 (0.72) | DKK1SORDHCAR2PIK3CAFAAH | |
| SCHEMBL3648686 | 0.79 | DKK1 (0.67) | DKK1PIK3CA | |
| SCHEMBL14507090 | 0.78 | ALDH1A1 (0.60) | DKK1SORDHCAR2PIK3CA | |
| SCHEMBL16761846 | 0.77 | KDM4E (0.56) | — | |
| SCHEMBL2225874 | 0.76 | KMT2A (0.57) | DKK1SORDHCAR2PIK3CA | |
| SCHEMBL1275203 | 0.76 | SORD (0.61) | SORDHCAR2 | |
| SCHEMBL1729056 | 0.75 | DKK1 (0.66) | DKK1SORDHCAR2HCRTR1HCRTR2 | |
| SCHEMBL2225622 | 0.75 | HCAR2 (0.65) | SORDHCAR2HCRTR1HCRTR2PIK3CA | |
| Hydrochloric Acid SCHEMBL3272283 | 0.74 | ALDH1A1 (0.57) | DKK1SORDHCAR2PIK3CA | |
| SCHEMBL16689602 | 0.73 | RBP4 (0.73) | DKK1SORDHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118510775-A | Isoxazolidines as RIPK1 inhibitors and their use | 建新公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203027-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | DKK1 1855/4885SORD 2773/4885HCAR2 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.